APPENDIX Z. ZHANG ET AL. "INHIBITION OF HBV REPLICATION BY A FULLY HUMANIZED NEUTRALIZING ANTIBODY *IN VIVO* AND *IN VITRO*"


Fig. S1. AST/ALT levels in mouse plasma after dose injection. Data were presented as mean± Standard error of each group of mouse samples unless otherwise specified

Table 1. Virus Information Sheet

Name	Batch No.	Titer (GE/ml)	Genotype	Source
HBV	20211216-3	8.00E+8	D	HepG2.2.15 cell supernatant
HBV	20220315-B1	6.13E+9	B	Plasmid transfected HepG2 cell culture supernatant
HBV	20220315-C3	6.51E+9	C	Plasmid transfected HepG2 cell culture supernatant

Table 2. Main reagents

Name	Brand	Batch No.
QIAamp 96 DNA Blood Kit (12)	Qiagen	51162
FastStart Universal Probe Master (Rox)	Roche	04914058001
Quantitative Test Kit for Hepatitis B Surface Antigen (HBsAg) Assay	Autobio	CL0310
SensiFAST SYBR Hi-ROX Kit	Meridian Bioscience	BIO-92005
DNesasy Biood&Tissue kit (50)	Qiagen	6950
AST	Beckman	OSR6109
ALT	Beckman	OSR6107

Table 3. Main instruments

Name	Brand	Model
Enzyme-linked immunosorbent assay (ELISA)	BioTek	Synergy 2
Fluorescence Quantitative PCR Instrument	Applied Biosystems	7900HT Fast Real-time PCR system
Multi-function Readout Machine	Molecular Device	SpectraMax iD3
Fragmentation Analyzer	Qiagen	Tissue Lyser II
Fluorescence Quantitative PCR Instrument	ABI	QuantStudio™ 6 Flex
Spectrophotometer	Thermo	Spectrophotometer Nanodrop 1000
Centrifuge	Beckman	Allegra-X15R
Automatic biochemical analyzer	Beckman	AU480

Table 4. The ADCC effect of positive and negative control antibodies

Concentration μg/ml	100	20	4	0.8	0.16	0.032	0.0064	0
Positive control – Rituximab	53.03%	56.47%	54.31%	41.28%	33.25%	26.94%	13.57%	0
Negative control – human IgG1	-7.35%	/	/	/	/	/	/	/

Table 5. The ADCC effect of the test antibody

Concentration µg/ml	100	20	4	0.8	0.16	0.032	0.0064	0
HT-102(BM012)	–3.85%	–1.41%	1.00%	0.80%	1.97%	0.03%	1.08%	0
Negative control – human IgG1	-2.88%	/	/	/	/	/	/	/

Table 6. The CDC effect of positive and negative control antibodies

Concentration µg/ml	100	20	4	0.8	0.16	0.032	0.0064	0
Positive control – Rituximab	15.59%	12.73%	15.28%	19.53%	14.87%	2.87%	0.68%	0
Negative control – human IgG1	0.15%	/	/	/	/	/	/	/

Table 7. The CDC effect of the test antibody

Concentration µg/ml	100	20	4	0.8	0.16	0.032	0.0064	0
HT-102(BM012)	5.23%	3.05%	1.12%	2.21%	3.06%	0.33%	0.71%	0
Negative control – human IgG1	-0.13%	/	/	/	/	/	/	/